Drug intelligence / Profile preview

IDC334

Development stage: Preclinical
Lead developer: Prestige Biopharma
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

IDC334 is a novel monoclonal antibody currently in the preclinical development stage for the treatment of solid tumors. Developed by Prestige Biopharma, it is categorized within their "Innovative Drugs" pipeline as a "Novel Concept Antibody." As of the current pipeline status, the drug is in the lead identification phase. Specific details regarding its biological target and exact mechanism of action have not been publicly disclosed by the developer, though it is being positioned as a potential therapeutic for various solid malignancies.

Beyond the preview

Go deeper on IDC334.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IDC334.

Explore the full profile